• Proceedings of the Korean Vacuum Society Conference
• /
• 2013.02a
• /
• pp.201-201
• /
• 2013

ITO는 투명하면서도 전도성이 매우 높은 물질로 디스플레이 분야에서 전극으로 많이 사용된다. 하지만 ITO는 세라믹 물질이기 때문에 공정 단가가 높고, 유연성이 낮아 구부릴 경우 전도성이 파괴되며 충격에도 약하여 flexible한 소자에 적용할 수 없다. 또한 metal diffusion이 잘 일어나는 물질이기 때문에 OLED 소자의 특성을 저해한다. 이와 같은 문제점을 해결하기 위해 ITO를 대체하여 graphene을 이용한 투명전극 연구개발이 활발히 진행되고 있다. Graphene은 높은 mobility와 전도도를 가지고 있으며, 높은 열전도성, Young's modulus, 그리고 mechanical flexibility를 가진 물질이다. 최근에 이러한 장점들로 인해 ITO를 대체하는 물질로서 각광을 받고 있지만 graphene은 Cu, Ni과 같은 금속표면에 한정되어 성장하는 문제점을 가지고 있다. 이 graphene 합성방법은 전사과정을 필요로 하며, 이로 인해 낮은 생산성과 낮은 수율을 야기한다. 최근 높은 생산성을 가지는 graphene 전극을 만들기 위해 Reduced Graphene Oxide (rGO) 연구가 활발히 진행되고 있다. 그러나 rGO는 산화환원 과정에서 전기전도도와 electron mobility가 완벽히 회복되지 못한다는 문제점을 가지고 있다. 그리하여 본 연구에서는 높은 투과도와 높은 전도도를 갖는 graphene 전극을 얻기 위해서 powdered graphene flake를 사용하였다. Graphene flake를 IPA solvent에 분산시키기 위해 sonicator과 homogenizer를 이용하여 Graphene flake solution을 제작하였다. 그리고 uniform한 전극을 만들기 위해 Spray Coating 방법을 이용하여 PET 기판 위에 graphene flake를 증착시켰다. graphene flake를 이용하여 높은 투과도와 낮은 면저항을 갖는 투명전극을 제작하고, 그 특성을 UV-visible spectrophotometer과 four point probe를 이용하여 확인하였다.

• Journal of Radiopharmaceuticals and Molecular Probes
• /
• v.9 no.1
• /
• pp.23-33
• /
• 2023

Prostate cancer ranks as the world's second most frequently diagnosed cancer among men, and is responsible for the fifth highest number of cancer-related deaths in this population. The development of effective diagnostic and therapeutic approaches for prostate cancer remains a major challenge in the field of oncology. Over the past few years, the prostate-specific membrane antigen (PSMA) has raised as a hopeful tracer for the diagnosis and treatment of prostate cancer.Various radioisotopes, such as ¹³¹I, ^99mTc, ⁶⁸Ga, and ¹⁷⁷Lu, have been used to label PSMA analogues, with varying degrees of success. Among these, ⁶⁸Ga-PSMA-11 and ¹⁷⁷Lu-PSMA-617 have emerged as the most promising radioligands for clinical use. Recently, researchers have been exploring the use of other radioisotopes, such as ²¹¹At, ⁸⁹Zr, ^64/67Cu, and ^203/212Pb, for the labeling of PSMA-targeted radioligands. These radioisotopes have unique properties that may offer advantages over existing radioligands, such as longer half-lives, higher specific activities, and different emission profiles. Efforts are currently underway to develop these radiopharmaceuticals and make them more widely available for clinical use. These exciting developments highlight the potential of PSMA-targeted radioligands for the diagnosis and treatment of prostate cancer, and provided significant implications for the management of this disease in the future. The current study aims to provide a comprehensive summary of the latest research and clinical applications of radiolabeled PSMA inhibitors for diagnoses and therapy of prostate cancer, emphasizing the exciting developments in the field and their potential impact on clinical practice.

• Nuclear Medicine and Molecular Imaging
• /
• v.43 no.4
• /
• pp.330-336
• /
• 2009

Purpose: We established radiolabeling conditions of NOTA and DOTA with a generator-produced PET radionuclide $^{68}$Ga and studied in vitro characteristics such as stability, serum protein binding, octanol/water distribution, and interference with other metal ions. Materials and Methods: Various concentrations of NOTA 3HCl and DOTA 4HCl were labeled with 1 mL $^{68}$GaCl$_3$ (0.18$\sim$5.75 mCi in 0.1 M HCl in various pH. NOTA 3HCl (0.373 mM) was labeled with $^{68}$GaCl$_3$(0.183$\sim$0.232 mCi/0.1 M HCl 1.0 mL) in the presence of CuCl$_2$, FeCl$_2$, InCl$_3$, FeCl$_3$, GaCl$_3$, MgCl$_2$ or CaCl$_2$ (0$\sim$6.07 mM) at room temperature. The labeling efficiencies of $^{68}$Ga-NOTA and $^{68}$Ga-DOTA were checked by ITLC-SG using acetone or saline as mobile phase. Stabilities, protein bindings, and octanol distribution coefficients of the labeled compounds also were investigated. Results: $^{68}$Ga-NOTA and $^{68}$Ga-DOTA were labeled optimally at pH 6.5 and pH 3.5, respectively, and the chelates were stable for 4 hr either in the reaction mixture at room temperature or in the human serum at 37$^{\circ}C$. NOTA was labeled at room temperature while DOTA required heating for labeling. $^{68}$Ga-NOTA labeling efficiency was reduced by CuCl$_2$, FeCl$_2$, InCl$_2$, FeCl$_3$ or CaCl$_3$, however, was not influenced by MgCl$_2$ or CaCl$_2$. The protein binding was low (2.04$\sim$3.32%). Log P value of $^{68}$Ga-NOTA was -3.07 indicating high hydrophilicity. Conclusion: We found that NOTA is a better bifunctional chelating agent than DOTA for $^{68}$Ga labeling. Although, $^{68}$Ga-NOTA labeling is interfered by various metal ions, it shows high stability and low serum protein binding.